Treatment of acute nonlymphocytic leukemia in adults: Response to 2,2‐anhydro‐1‐B‐D‐Arabinofuranosyl‐5‐fluorocytosine and thioguanine on the L‐12 protocol Academic Article Article uri icon


MeSH Major

  • Cardiovascular Diseases
  • Genetic Variation
  • Indians, North American
  • Mannose-Binding Lectin


  • Fifty-one adult patients with acute nonlymphocytic leukemia (excluding acute promyelocytic leukemia) were treated on the L-12 protocol. The L-12 differed from the preceding L-6 in that 2,2-anhydro-1-B-D-arabinofuranosyl-5-fluorocytosine (AAFC), replaced arabinosylcytosine (ara-C) together with 6-thioguanine (TG) for remission induction. Achievement of remission was followed by an extended 14-week multi-drug consolidation program. With this more intense regimen, an overall complete remission rate of 49% and a median remission duration of 23.7 months were achieved; these results were not significantly better than the 57% complete remission rate and 8.6 months median remission duration obtained with the L-6 regimen. Four year disease-free survival was 22% on the L-12 compared with 16% on the L-6 protocol. No relationship between prognosis and FAB classification was found on either the L-6 or the L-12 protocol.

publication date

  • January 1981



  • Academic Article


Digital Object Identifier (DOI)

  • 10.1002/1097-0142(19811115)48:10<2136::AID-CNCR2820481003>3.0.CO;2-1

PubMed ID

  • 6170414

Additional Document Info

start page

  • 2136

end page

  • 42


  • 48


  • 10